Skip to content
Molecules
SEKISUI XenoTech DD Blog Logo

New Liver Disease Resource and Other Research Biobank News

SEKISUI XenoTech is committed to furthering the knowledge surrounding hepatic diseases, which affects one out of four people worldwide, such as nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). Over 20+ years of pharmacokinetic studies, we have accumulated normal and diseased tissues representing FLD with or without history of alcohol consumption and steatohepatitis in our Research Biobank.

As part of the Biobank, we have created a new fatty liver disease (FLD) progression infographic showing statistics and characteristics of tissues from normal states into steatosis, steatohepatitis and Non-alcoholic Steatohepatitis (NASH) into cirrhosis. Click here to view this new resource.

We also recently held a webinar on Drug Metabolizing Enzymes and Transporters in NASH. Click here to view this resource.

We have additionally begun offering human gallbladder tissue from matching donors with the human liver tissue samples. Furthermore, the Research Biobank donor information sheet now lists additional details, such as diabetes type, pediatric donors, and NASH donors have been listed in their own location with additional information for easier reference.

Tissues, subcellular fractions, paraffin blocks, slides & hepatocytes* are available. Learn more about the Research Biobank or contact us if you have any questions or to request a quote.

Learn more about:

*Hepatocytes have not been prepared for all donors. Please refer to the donor information sheet for availability.

About the Authors

Michael Millhollen received his bachelor's degree in Visual Communications from the University of Kansas and has over 20 years of experience in marketing and communications. As Global Marketing Manager, he is dedicated to the objective of sharing SEKISUI XenoTech’s scientific expertise and knowledge with scientists around the world.
Maciej Czerwinski currently serves as Director of Consulting at SEKISUI XenoTech. Maciej received his PhD from the University of Maryland at Baltimore Medical School in the Department of Pathology. He has been with SEKISUI XenoTech since 1999 and guides the development of products and services for the in vitro analysis of drug safety. Maciej designed a patented method to analyze the in vitro cytokine-mediated drug-drug interactions between biologics and small molecule drugs. Dr. Czerwinski is also the inventor of our patented CryostaX single-freeze pooled hepatocytes.

Subscribe to our Newsletter

Stay up to date with our news, events and research

In vitro pipette test article treatment
005 International Messaging Created with Sketch.

Do you have a question or a request for upcoming blog content?

We love to get your feedback

A scientist utlilizing a microplate